Point72 Asia (Singapore) Pte. Ltd. Larimar Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 500 shares of LRMR stock, worth $1,810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$1,810% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
127Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$76.9 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$21.9 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$20.2 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$15.4 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$15.1 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $157M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...